Further, we propose that the levels of MPO remaining within the ileum may act as a catalyst for Isoniazid metabolism into NAD+ adducts, reducing inflammation locally similarly to previously described mechanisms of neutrophil metabolic reprogramming.60 Overall, Isoniazid may present a novel anti-inflammatory therapy for the treatment of IBD, one whose mechanisms are likely scarcely known but show promise.63 This evidence concerns the gene MPO and inflammatory bowel disease.